Connect with us

JAMMU & KASHMIR

DAK urges doctors to use hydroxychloroquine for Coronavirus patients | KNO

Published

on

kno news

Srinagar, Mar 28 (KNO): With 21 positive cases and a death due to the novel (new) coronavirus in Kashmir valley so far, Doctors Association Kashmir (DAK) on Saturday has urged doctors to use arthritis drug, hydroxychloroquine for patients who are diagnosed with the viral infection. “That would save lives and prevent spread of the disease,” said DAK President Dr Nisar ul Hassan in a statement to wire service—Kashmir News Observer (KNO). “A French study published in the International Journal of Antimicrobial Agents has shown promising results for hydroxychloroquine as a treatment for the virus, and when used with Azithromycin, it significantly reduced the viral load,” he said. “According to the study, at day 6 of treatment 70 percent of the patients who received hydroxychloroquine had cleared the virus and 100 percent of the patients treated with hydroxychloroquine and azithromycin combo were virologically cured,” he added. Dr Nisar said weighing the findings, the results are enough for us to recommend the treatment for COVID-19 patients, considering the graveness of the pandemic and the lack of available treatment. He said in addition to the direct therapeutic role, combo drug can play a role in controlling the disease epidemic by limiting the duration of virus shedding which can last for several weeks in the absence of specific treatment. Dr Nisar said the combo treatment could prevent severe disease and spare the hospitals and healthcare systems from most expensive and invasive care of ICU’s and ventilators. “Clinicians across the world are using the drug combo, and it is working and saving lives,” he said. “We can’t see people dying. We can’t deny an off-label drug to a patient when it is backed by solid scientific evidence,” Dr Nisar said. “Off-label means to use the drug for other reasons than what the FDA has approved the drug for,” he said adding “a doctor is legally free to prescribe a drug for any reason that he or she thinks is medically appropriate, and when there are no other options available,” he said. “ICMR has recommended hydroxychloroquin as a preventive medication for healthcare workers and household contacts of confirmed cases. The recommendation needs to be expanded, and clinicians should be authorized to use the drug for treatment. The restrictive use will take a heavy toll on patients and the community at large,” cautioned Dr Nisar—(KNO)

Trending

TOP STORIES2 hours ago

MeT predicts light snow in J&K higher reaches between Dec 13 & 17 | KNO

TOP STORIES2 hours ago

J&K faces rainfall deficit, many springs, water bodies dry up | KNO

TOP STORIES2 hours ago

Kashmir transporters divided over Dec 15 strike | KNO

TOP STORIES2 hours ago

Chinese national deported for visa violations, Budgam homestay owner booked for concealing stay | KNO

TOP STORIES2 hours ago

IndiGo stabilising its operations at Srinagar Airport | KNO

TOP STORIES2 hours ago

Sopore youth’s body recovered in Vijaypur, family suspects foul play | KNO

TOP STORIES2 hours ago

Bulbul Nag in Newa dries up again, villages face severe water crisis | KNO

TOP STORIES2 hours ago

J&K, Ladakh get Rs 6,900 Cr boost for power sector | KNO

TOP STORIES2 hours ago

Jammu, Srinagar see 279 smart city projects completed; 9 more under execution: GoI | KNO

TOP STORIES2 hours ago

NHPC Executing Four Major Hydropower Projects in J&K Worth ₹25,945 Cr: Govt | KNO

TOP STORIES2 hours ago

‘J&K created over 78, 000 jobs under PMEGP’ | KNO

TOP STORIES2 hours ago

J&K sees 15.44 lakh e-challans last year: GoI | KNO

TOP STORIES2 hours ago

J&K records 831 road accident deaths in 2024 | KNO

TOP STORIES2 hours ago

J&K reports 5,808 road accidents in 2024: Centre | KNO

TOP STORIES2 hours ago

Govt aims for 158 km NH in J&K | KNO

TOP STORIES2 hours ago

J&K sees mere 13% Forest Rights Claims success Rate: GoI | KNO

TOP STORIES2 hours ago

No one will ever again glorify terrorists, separatists in J&K: LG Sinha | KNO

Copyright © 2021